Skip to content
Menu

Denali Therapeutics Inc. DNLI

Full chart Compare
Set alert

Price alert · DNLI

All alert types
18.45 USD +0.25 (+1.37%)

Regular-session close

18.45 0.00 0.00%

After hours · Nov 20, 4:52 PM ET

17.92 Day range 18.85
16.02 52-week range 27.21
YTD
+11.75%
1 year
+7.52%

5D -1.00 (-5.15%)

171819ThuFriMonTueWed18.40
Market cap
2.96B
Revenue (ttm)
21.38M
EPS (ttm)
-1.72
Shares out
160.29M
Forward P/E
-8.16
YTD return
+11.75%
1-year return
+7.52%
50-day average
19.48
200-day average
21.15
Enterprise value
2.44B
Volume
2.63M
Avg volume
1.64M
Open
17.95
Previous close
18.20
Day's range
17.92 – 18.85
52-week range
16.02 – 27.21
Beta
1.08
Analysts
Strong Buy
Price target
35.82 (+94.2%)
Earnings date
Feb 25, 2027

Key statistics

Price / sales
138.16
Price / book
3.19
Free cash flow
-301.32M
Total cash
516.20M
Total debt
35.24M
Return on equity
-33.94%
Short % of float
9.67%

Fundamental scorecard

4 of 25 checks passed on DNLI’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
DNLI Revenue — quarterly 17.78M
DNLI Net income — quarterly 70.13M
DNLI EPS — quarterly 0.37

Earnings

DNLI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-0.61———
Nov 3, 2026Sep 30, 2026-0.270940.37+0.64+236.56%
Aug 6, 2026Jun 30, 2026-0.51305-0.68-0.17-32.54%
May 7, 2026Mar 31, 2026-0.73-0.69+0.04+5.48%
Feb 26, 2026Dec 31, 2025-0.75-0.73+0.02+2.67%
Nov 6, 2025Sep 30, 2025-0.76-0.74+0.02+2.63%

Upgrades / downgrades

DNLI analyst upgrades and downgrades
DateFirmActionFromTo
Nov 4, 2026Morgan StanleymainOverweightOverweight
Nov 4, 2026WedbushmainOutperformOutperform
Nov 4, 2026BTIGreitBuyBuy
Aug 25, 2026B. Riley SecuritiesmainBuyBuy
Aug 7, 2026UBSmainBuyBuy
Jul 23, 2026Morgan StanleymainOverweightOverweight

About Denali Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on DNLI — it syncs with the Stock Master app.

Insider holders

DNLI insider holders
InsiderRelationLatest transactionDateShares held
BAKER BROS ADVISORS, L.P.Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Jun 2, 20260
CHIN PETER SCOTTOfficerSaleSep 3, 2026204,538
FLATLEY JAY TDirectorStock Award(Grant)Jun 2, 2026358,941
HO CAROLEOfficerSaleAug 12, 2025424,804
KROGNES STEVE EDirectorStock Award(Grant)Jun 2, 2026819,999
SATO VICKI LEEDirectorSaleJan 1, 2025107,976

Institution ownership

DNLI institution ownership
Holder% heldSharesValueReported
T. Rowe Price Investment Management, Inc.12.24%19,617,453361.55MSep 29, 2026
Blackrock Inc.8.94%14,328,688264.08MSep 29, 2026
BAILLIE GIFFORD & CO6.94%11,119,945204.94MSep 29, 2026
Temasek Holdings (Private) Ltd4.38%7,012,974129.25MSep 29, 2026
Vanguard Portfolio Management LLC4.22%6,758,410124.56MSep 29, 2026
Vanguard Capital Management LLC4.21%6,751,225124.43MSep 29, 2026

Fund ownership

DNLI fund ownership
Holder% heldSharesValueReported
T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App3.10%4,966,70091.54MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.68%4,288,39179.04MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.38%3,813,51570.28MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.93%3,097,18357.08MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.91%3,055,33156.31MSep 29, 2026
VANGUARD WORLD FUND-Vanguard U.S. Growth Fund1.67%2,681,18449.41MAug 30, 2026